All In Biotech

Drug Trial Radar · NCT07931547

A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes and Chronic Kidney Disease Inadequately Controlled on Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Jul 31, 2028

Study completion Sep 25, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is testing zenagamtide in participants with type 2 diabetes and chronic kidney disease. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or placebo. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

Conditions

  • Type 2 Diabetes
  • Chronic Kidney Disease

Interventions

  • PlaceboOther

    Placebo matched to zenagamtide will be administered subcutaneously once weekly.

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 52

Locations

125 sites in 10 countries. Site status is shown where the registry gives one.

  • Scripps Whittier Diabetes Inst

    La Jolla, California

  • First Valley Medical Group

    Lancaster, California

  • Headlands Research CTR Lincoln

    Lincoln, California

  • North America Research Institute

    San Dimas, California

  • Northeast Research Institute

    Fleming Island, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • My Preferred Research

    Miami, Florida

  • Adult Medicine of Lake County, Inc

    Mt. Dora, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Florida Inst For Clin Res LLC

    Orlando, Florida

  • Care Access

    Tamarac, Florida

  • Encore Medical Research of Weston

    Weston, Florida

  • Palm Research Center Inc-Vegas

    Las Vegas, Nevada

  • DM Clinical

    Brooklyn, New York

  • University of North Carolina Chapel Hill

    Chapel Hill, North Carolina

  • Carteret Medical Group

    Morehead City, North Carolina

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • Holston Medical Group Pc

    Bristol, Tennessee

  • Southeast Renal Research Institute

    Chattanooga, Tennessee

  • Clinical Research Associates

    Nashville, Tennessee

  • Victorium Clinical Research

    Houston, Texas

  • Prolato Clinical Research Cntr

    Houston, Texas

  • Southwest Clinical Trials

    Houston, Texas

  • Medical Colleagues-Texas LLP

    Katy, Texas

  • Northeast Clinical Research of San Antonio

    San Antonio, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • Hospital de Clínicas de Porto Alegre_Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto de Pesquisa Clínica de Campinas

    Campinas, São Paulo, Brazil

  • CPQuali Pesquisa Clínica Ltda

    São Paulo, São Paulo, Brazil

  • The Second People's Hospital of Hefei-Endocrinology

    Hefei, Anhui, China

  • Chongqing University Three Gorges Hospital-Endocrinology

    Chongqing, Chongqing Municipality, China

  • Huizhou Central People's Hospital-Endocrinology

    Huizhou, Guangdong, China

  • The Second People's Hospital of Shenzhen-Endocrinology

    Shenzhen, Guangdong, China

  • Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology

    Hengshui, Hebei, China

  • The Second Hospital of Hebei Medical University-Endocrinology

    Shijiazhuang, Hebei, China

  • Huaihe Hospital of Henan University-Endocrinology

    Kaifeng, Henan, China

  • Luoyang First People's Hospital-Endocrinology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Nanyang Medical College-Endocrinology

    Nanyang, Henan, China

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.